VRCA vs VTGN

Verrica Pharmaceuticals Inc. vs VistaGen Therapeutics, Inc. — Valuation Comparison 2026

VRCA

Biotechnology
Verrica Pharmaceuticals Inc.
Quality
5.4
out of 10
Value Trap
30
LOW
Price
$6.04
Last close
Models
8/13
Active
VS

VTGN

Biotechnology
VistaGen Therapeutics, Inc.
Quality
6.0
out of 10
Value Trap
32
LOW
Price
$0.63
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType VRCA Fair ValueVRCA Upside VTGN Fair ValueVTGN Upside
Bayesian DCF Intrinsic $1.50 -75.1% $0.81 +27.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.61 -56.8% $2.62 +313.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VRCA vs VTGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VRCA vs VTGN — Which Stock Is More Undervalued?

VTGN scores higher with a 6.0/10 quality rating vs VRCA's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Verrica Pharmaceuticals Inc. (VRCA) and VistaGen Therapeutics, Inc. (VTGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VRCA currently trades at $6.04 with a QOC of 5.4/10, while VTGN trades at $0.63 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).